Clinical Trials

Clinerion's Patient Network Explorer will leverage Maxer's extended network of relations in the international healthcare sector to access promising business opportunities and expand Clinerion’s patient coverage into Italy, promoting and delivering clinical trials-related solutions. Clinerion and Maxer will cooperate to...

Bayer announced the submission of the regulatory application seeking the approval of vericiguat in China. Vericiguat is an investigational oral, once-daily, first-in-class soluble guanylate cyclase (sGC)-stimulator being developed to treat patients with symptomatic chronic heart failure with an ejection...

Serum Institute of India’s trial for ‘Covishield’ vaccine developed by the University of Oxford started with the first patients screened by Bharati Vidyapeeth Deemed University (BVDU) Medical College and Hospital in Pune. We have screened some patients. Tomorrow, we will...

A COVID-19 vaccine candidate being developed by Australia’s University of Queensland has shown “positive” results against the novel coronavirus in preclinical tests, raising hopes for its potential effectiveness and manufacturability, the varsity said on Wednesday. According to the yet-to-be published...

Trialbee, a leading global technology provider for patient matching and engagement in clinical trials, announced a partnership with Clinerion, a worldwide leader in medical data informatics with a global research network comprised of 30.2 million patients online across 69...

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19. The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics...

Bristol Myers Squibb announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine...